ORM was co-founded in 2009 by Bruce Edelen and Ron Schleif, who together have more than 35 years of experience within oncology. We combine deep market understanding and technical expertise with long-standing relationships with key influencers and pivotal decision-makers to advance our customers’ access and reimbursement strategies.
Ron has nearly 40 years of experience in the pharmaceutical industry. Ron was with Eli Lilly and Company for 25 years, 15 of which were spent focused on oncology, where he developed successful global launch strategies and led the U.S. marketing and sales organizations.
Bruce has nearly 40 years of experience in the pharmaceutical industry. During three decades at Eli Lilly and Company, Bruce worked in a series of roles in oncology including pricing, reimbursement and access, sales management, sales training, HR and sales operations. Bruce developed and led the oncology reimbursement team at Lilly for eight years and was instrumental in developing the pricing and contracting strategy for all oncology marketed products during his tenure, including playing a pivotal role in pricing, reimbursement and access for pipeline oncology products.
With over 15 years of pharmaceutical marketing experience, Natasha has been instrumental in commercial wins across global new product development and US demand generation assignments, including oncology. At Eli Lilly and Company, she was recognized for successful launch planning and implementation, strategic brand planning, thought leader engagement, and value proposition development—considering provider, patient and payer perspectives. With ORM, Natasha distills diverse, access-centric research and data in to the most salient, actionable insights affording targeted implementation that advances client success.
Tarek has acquired over 30 years of experience in the pharmaceutical industry, with the last 20 years focused on the American and Canadian oncology marketplaces. He has served in a variety of management and leadership roles, including Sales Manager, Product Manager, Affiliate Oncology Team Leader, Director of US Oncology Payer Marketing and Global Marketing Director for Oncology Products. He has been instrumental in leading new oncology product launches, securing access to and reimbursement in challenging markets, and designing and executing effective pricing and contracting strategies, Tarek is recognized for building strong collaborations with key healthcare stakeholders and decision makers, and for developing and executing strategic plans for successful oncology product commercialization.
What Our Customers Say
Understanding where patients, providers and producers intersect is a rare skill that only a few possess. Bruce and Ron are right there and this is a benefit to everyone in cancer.
Christian G. Downs Executive Director Association of Community Cancer Centers (ACCC)
I have had the opportunity to know and work with Bruce and Ron since 1998. I have found them to be of high integrity, thoughtful and proficient around their business, and extremely well-networked. Their focus on the customer is remarkable.
Linda S. House President Cancer Support Community
Ron and Bruce know the “ins and outs” of the oncology market ecosystem better than anyone. Their contribution to several projects was invaluable in developing on-point solutions for our clients.
Lee Blansett Principal & Founder Proximity Health
Bruce and Ron have been involved in understanding and leveraging the changing oncology landscape for a long time. They understood the early impact of GPOs and they leveraged the entry of disease management companies into the space. They are practical, straightforward individuals that look for win-win situations in the marketplace.
Raj Mantena CEO Integra Connect
I have known Bruce Edelen since 2001 and over the past nine years have had the distinct pleasure of partnering with him and Ron Schleif on numerous patient assistance and reimbursement support projects. Their oncology reimbursement expertise, coupled with their aptitude for building relationships, has not only provided great value to their customers, but has also enabled them to positively impact the lives of many underserved cancer patients.
Scott Dulitz Chief Strategy Officer & Head of Corporate Development Trialcard